Agenus Inc. (AGEN)
3.14
-0.00 (-0.16%)
At close: Jan 15, 2025, 11:37 AM
undefined% (undefined)
| Bid | 3.14 |
| Market Cap | 73.66M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -11.02 |
| PE Ratio (ttm) | -0.28 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 3.16 |
| Volume | 75,644 |
| Avg. Volume (20D) | 505,006 |
| Open | 3.26 |
| Previous Close | 3.15 |
| Day's Range | 3.14 - 3.29 |
| 52-Week Range | 2.50 - 19.69 |
| Beta | undefined |
About AGEN
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 8, 2000
Employees 389
Stock Exchange NASDAQ
Ticker Symbol AGEN
Website https://www.agenusbio.com
Analyst Forecast
According to 3 analyst ratings, the average rating for AGEN stock is "Hold." The 12-month stock price forecast is $10.5, which is an increase of 234.39% from the latest price.
Buy 33.33%
Hold 66.67%
Sell 0.00%
Next Earnings Release
Agenus Inc. is scheduled to release its earnings on Mar 13, 2025,
before market opens.
Analysts project revenue of $33.49M, reflecting a -60.04% YoY shrinking and earnings per share of -2.66, making a 2.31% increase YoY.
Analysts project revenue of $33.49M, reflecting a -60.04% YoY shrinking and earnings per share of -2.66, making a 2.31% increase YoY.
6 months ago ·
Source
-58.83%
Agenus shares are trading lower after the company ...
Unlock content with
Pro Subscription
9 months ago ·
Source
-8.12%
Agenus shares are trading lower. The company announced updated results from its Phase 1 clinical trial of BOT/BAL combination therapy in patients with metastatic CRC that is not microsatellite instability-high or deficient mismatch repair.
